While these data suggest ILCs as mechanistic drivers and potential biomarkers in SSc, key questions remain regarding their precise temporal roles, the molecular circuits governing their activation, and the potential for targeted modulation of ILC subsets to mitigate fibrosis. The gene discussed is CCL27; the disease is systemic sclerosis.